Archives
-
CDK4/6 and BET Inhibition in Pancreatic Cancer
2026-10-04
Gu et al. show that CDK4/6 inhibition can suppress pancreatic ductal adenocarcinoma growth while paradoxically increasing migration, invasion, and epithelial-to-mesenchymal transition. Their study identifies combined CDK4/6 and BET inhibition as a preclinical strategy that counteracts this phenotype through interactions among GSK3β-mediated Wnt/β-catenin signaling and TGF-β/Smad pathways.
-
How Kinase Inhibitors Shape p38α Dephosphorylation
2026-10-03
The reference preprint identifies a dual-action mechanism in which selected kinase inhibitors both inhibit p38α catalytic activity and increase WIP1-mediated dephosphorylation of its activation-loop phosphothreonine. Biochemical evidence and X-ray structures connect this effect to an inhibitor-stabilized activation-loop conformation, while also defining the limits of extending these findings to cellular or disease models.
-
JNK-IN-7 in Infection-Driven Apoptosis Research
2026-10-02
JNK-IN-7 provides a selective JNK inhibitor framework for testing how Candida krusei morphology, innate immune signaling, and apoptosis intersect. This article translates phase-specific infection findings into practical assay decisions for c-Jun phosphorylation and MAPK pathway research.
-
Prednisolone: Glucocorticoid Research Guide
2026-10-01
Prednisolone is a synthetic glucocorticoid used to investigate glucocorticoid receptor signaling, inflammation modulation, and cellular responses to corticosteroids. Its formulation limits and its distinction from the desonide-based ERAD technology reported in 2026 should guide experimental design.
-
H-89: PKA Inhibition in cAMP Signaling
2026-10-01
H-89 is a cAMP-dependent protein kinase inhibitor used to test protein kinase A inhibition in biochemical and cellular experiments. The product information reports a 48 nM IC50, but that value is an assay benchmark rather than a universal cellular treatment concentration.
-
SB 202190: p38 MAP Kinase Inhibitor Guide
2026-09-30
SB 202190 combines nanomolar p38α/β inhibition with cell permeability, making it useful for linking kinase activity to cytokine output, apoptosis, and invasive-cell behavior. This workflow adapts a high-content extracellular-matrix internalization strategy to help distinguish pathway-specific migration effects from general cytotoxicity.
-
CPSIT_0844, TLR2/4, and JNK-Linked Inflammation
2026-09-30
The reference study identifies the Chlamydia psittaci inclusion membrane protein CPSIT_0844 as a proinflammatory stimulus that induces IL-6 and IL-8 in human monocytes through TLR2/TLR4–MyD88 signaling. Its experimental design connects receptor perturbation with activation of JNK, p38, and NF-κB, providing a mechanistic framework for studying C. psittaci-driven inflammation and cytokine expression modulation.
-
KX2-391 Dihydrochloride: Mechanism to Assay
2026-09-29
KX2-391 dihydrochloride, also called Tirbanibulin dihydrochloride, connects Src inhibition, tubulin disruption, HBV transcriptional control, and BoNT/A research. This article explains how to separate direct evidence from analog-based findings and design assays that preserve mechanistic meaning.
-
Prednisolone: Glucocorticoid Research Workflows
2026-09-29
Build reproducible assays for glucocorticoid receptor activation, inflammation modulation, and cellular response to corticosteroids with Prednisolone. This guide also distinguishes established receptor pharmacology from the ERAD-hijacking degradation platform reported for transmembrane proteins.
-
Rotenone and the Mitochondrial Stress Decision Point
2026-09-28
Rotenone is more than a mitochondrial Complex I inhibitor: it is a controllable stress perturbation for connecting electron-transfer failure with ROS, energy loss, inflammasome signaling, and regulated cell death. This thought-leadership article translates findings from diabetic cardiomyopathy research into a practical framework for neurodegenerative disease research, assay design, and translational model selection.
-
EphA2 Vulnerability in MYC-Driven TNBC
2026-09-28
A chemogenetic screen of approximately 600 kinase inhibitors identified the EphA2 inhibitor ALW-II-41-27 as selectively cytotoxic to MYC-activated cells. The study links this response to intrinsic apoptosis and reports reduced tumor growth in two TNBC xenograft models, while leaving important questions about EphA2-specific dependence and clinical translation open.
-
HDAC Inhibition Reverses EBV-Driven NPC Dedifferentiation
2026-09-27
The study identifies an epigenetic route by which EBV LMP1 promotes a dedifferentiated, stem-like state in nasopharyngeal carcinoma: STAT5A-associated recruitment of HDAC1/2 represses CEBPA. In NPC models, HDAC inhibition restored CEBPA and reversed features of this state, providing a mechanistic rationale for testing differentiation therapy in solid tumors while leaving clinical efficacy and broader applicability to be established.
-
BMS 309403 for FABP4-Linked Foam Cell Research
2026-09-26
Use BMS 309403 to test whether FABP4 activity connects altered fatty-acid handling to macrophage foam-cell formation. This workflow pairs dose-ranging and lipid readouts with pathway controls, while distinguishing pharmacological evidence from genetic validation.
-
Resveratrol Suppresses EMT in GBM Through Smad Signaling
2026-09-25
A 2019 study found that resveratrol reduced TGF-β1-induced EMT-like changes, migration, invasion, and stem cell-associated features in glioblastoma models. Its combination of molecular, functional, and xenograft analyses supports Smad-dependent signaling as a mechanism, while leaving dose selection, model generalizability, and clinical relevance for further study.
-
GDC-0994: ERK Signaling Across Research Domains
2026-09-25
ERK1/2 is a convergence point in oncogenic signaling and estrogen-associated cholestatic injury. This translational perspective examines how GDC-0994 can help test pathway dependence, connect target engagement to phenotype, and guide careful interpretation across cancer and liver models.